Key result
NT-proBNP measurement is suggested for heart failure patients receiving ARNI therapy because its concentrations, unlike BNP, are not affected by neprilysin inhibition.
Why the study?
How should natriuretic peptides be used to assess and manage heart failure patients receiving ARNI therapy?
How should natriuretic peptides be used to assess and manage heart failure patients receiving ARNI therapy?
Answers are grounded in this paper and cite their sources.
NT-proBNP is the preferred biomarker for heart failure patients on ARNI therapy because its levels are not affected by neprilysin inhibition, whereas BNP levels may be artificially elevated.
Levels of natriuretic peptides (NPs), such as B-type NP (BNP) and the N-terminal fragment of its prohormone (NT-proBNP), are well-established biomarkers for patients with heart failure (HF). Although these biomarkers have consistently demonstrated their value in the diagnosis and prognostication of HF, their ability to help clinicians in making treatment decisions remains debated. Moreover, some new HF drugs can affect concentrations of NPs, such as the prevention of BNP degradation by angiotensin receptor/neprilysin inhibitors (ARNIs), and may present a challenge in the interpretation of levels of BNP. Use of NT-proBNP measurement has been suggested in the context of ARNI therapy because its concentrations are not affected by neprilysin inhibition. As biomarkers are reconsidered in the context of ARNI therapy, cutoff levels and the effects of individual patient characteristics, such as renal function and age, on biomarker concentrations should be reassessed.
No takes yet. Share an insight, caveat, or question.
Maisel et al. (2018) conducted a review in Heart failure. NT-proBNP measurement vs. BNP measurement was evaluated. NT-proBNP measurement is suggested for heart failure patients receiving ARNI therapy because its concentrations, unlike BNP, are not affected by neprilysin inhibition.
Synapse has enriched 10 related papers. Consider them for comparative context: